Mon, Mar 18|
The Only CDK4 & 6 Inhibitor Approved Across HR+, HER2- MBC in Combination and as a Single Agent
Verzenio is indicated for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2 negative advanced or metastatic breast cancer.
Time & Location
Mar 18, 2019, 5:30 PM
Tuscan Kitchen, 67 Main St, Salem, NH 03079, USA
About The Event
Yelena Novik, MD
Perlmutter Cancer Center
NYU Langone Health New York NY
This program will present efficacy and safety data for Verzenio, a CDK4 & 6 inhibitor approved in combination with fulvestrant, I combination with an Al, and as a single agent for HR+, HER2- advanced or MBC. Information about mechanism of action and dosing will also be presented.
- Discuss the unmet needs for women with HER+, HER2- MBC
- Examine the efficacy and safety profile of Verzenio
- Review practical considerations for the use of Verzenio
RSVP to Aimee Ferry